CFDE Data Portal | Search H4C16

	Label	Description
	H4C16 Gene (Entity type)	ENSG00000197837 - H4 histone 16
	GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 9 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE128885 deferiprone macrophage 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE225901 dexamethasone 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE203329 HCC knockout 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE176008 pyridoxine 7 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE173201 cisplatin 2 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE258991 enzalutamide DK1 [Tursiops] 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 4 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE164529 tamoxifen 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

H4C16

ENSG00000197837 - H4 histone 16

GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 9 v 2 human dn

A Gene Set from LINCS

GSE128885 deferiprone macrophage 0 v 2 human up

A Gene Set from LINCS

GSE225901 dexamethasone 2 v 1 human dn

A Gene Set from LINCS

GSE203329 HCC knockout 2 v 1 human up

A Gene Set from LINCS

GSE176008 pyridoxine 7 v 3 human dn

A Gene Set from LINCS

GSE173201 cisplatin 2 v 3 human dn

A Gene Set from LINCS

GSE258991 enzalutamide DK1 [Tursiops] 1 v 0 human up

A Gene Set from LINCS

GSE239844 crizotinib 4 v 5 human dn

A Gene Set from LINCS

GSE164529 tamoxifen 0 v 1 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.